Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89015 | 0.95 | CNR2 (0.55) | CNR2SMPD1PDE4APDE4BPDE4C | |
| SCHEMBL2473674 | 0.86 | MEN1 (0.65) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2087745 | 0.86 | LRRK2 (0.49) | CNR2MAPK14F10MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9639296 | 0.85 | MEN1 (0.64) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL90493 | 0.84 | HTR7 (0.50) | CNR2MAPK14 | |
| SCHEMBL3489257 | 0.84 | F10 (0.51) | CNR2SMPD1TP53PDE4APDE4B | |
| SCHEMBL8238436 | 0.84 | MAPK14 (0.52) | CNR2MAPK14F10MEN1ALPL | |
| SCHEMBL88998 | 0.82 | CA12 (0.67) | SMPD1TP53PDE4APDE4BPDE4C | |
| SCHEMBL3143526 | 0.81 | KMT2A (0.74) | MEN1ALPLKMT2ACYP2D6CYP2C9 | |
| SCHEMBL11687058 | 0.81 | KMT2A (0.74) | MEN1ALPLKMT2ACYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | CNR2 1820/4885SMPD1 1027/4885TP53 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.